JP7572041B2 - 重症喘息を処置するための組成物および方法 - Google Patents

重症喘息を処置するための組成物および方法 Download PDF

Info

Publication number
JP7572041B2
JP7572041B2 JP2020567470A JP2020567470A JP7572041B2 JP 7572041 B2 JP7572041 B2 JP 7572041B2 JP 2020567470 A JP2020567470 A JP 2020567470A JP 2020567470 A JP2020567470 A JP 2020567470A JP 7572041 B2 JP7572041 B2 JP 7572041B2
Authority
JP
Japan
Prior art keywords
asthma
antibody
pharmaceutical composition
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515039A (ja
JP2021515039A5 (https=
JPWO2019169015A5 (https=
Inventor
コネリー，スティーヴン
エヌジー，シェリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Equillium Inc
Original Assignee
Equillium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equillium Inc filed Critical Equillium Inc
Publication of JP2021515039A publication Critical patent/JP2021515039A/ja
Publication of JP2021515039A5 publication Critical patent/JP2021515039A5/ja
Publication of JPWO2019169015A5 publication Critical patent/JPWO2019169015A5/ja
Application granted granted Critical
Publication of JP7572041B2 publication Critical patent/JP7572041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020567470A 2018-02-27 2019-02-27 重症喘息を処置するための組成物および方法 Active JP7572041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636092P 2018-02-27 2018-02-27
US62/636,092 2018-02-27
PCT/US2019/019872 WO2019169015A1 (en) 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma

Publications (4)

Publication Number Publication Date
JP2021515039A JP2021515039A (ja) 2021-06-17
JP2021515039A5 JP2021515039A5 (https=) 2022-03-07
JPWO2019169015A5 JPWO2019169015A5 (https=) 2022-03-07
JP7572041B2 true JP7572041B2 (ja) 2024-10-23

Family

ID=65724591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567470A Active JP7572041B2 (ja) 2018-02-27 2019-02-27 重症喘息を処置するための組成物および方法

Country Status (14)

Country Link
US (2) US20210380711A1 (https=)
EP (1) EP3759140A1 (https=)
JP (1) JP7572041B2 (https=)
KR (1) KR20200128415A (https=)
CN (1) CN112424226B (https=)
AU (1) AU2019228508A1 (https=)
BR (1) BR112020017445A2 (https=)
CA (1) CA3091920A1 (https=)
IL (1) IL276875A (https=)
MX (1) MX2020008916A (https=)
PH (1) PH12020551323A1 (https=)
SG (1) SG11202008149RA (https=)
WO (1) WO2019169015A1 (https=)
ZA (1) ZA202005320B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
AU2021392748A1 (en) * 2020-12-04 2023-06-29 Equillium, Inc. Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014198710A (ja) 2013-03-13 2014-10-23 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2017038592A (ja) 2015-07-15 2017-02-23 協和発酵キリン株式会社 ヒトｃｒｔｈ２に特異的に結合する抗体
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
US20170362331A1 (en) 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Cd6 antibody for treatment of t-cell mediated diseases or disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CA2282410A1 (en) 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CN102559636B (zh) * 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014198710A (ja) 2013-03-13 2014-10-23 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
JP2017038592A (ja) 2015-07-15 2017-02-23 協和発酵キリン株式会社 ヒトｃｒｔｈ２に特異的に結合する抗体
US20170362331A1 (en) 2016-06-15 2017-12-21 The Cleveland Clinic Foundation Cd6 antibody for treatment of t-cell mediated diseases or disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Allergy, 2011, Vol.66, p.989-998
Current Drug Targets, 2016, Vol.17, p.666-677

Also Published As

Publication number Publication date
PH12020551323A1 (en) 2021-04-26
JP2021515039A (ja) 2021-06-17
AU2019228508A1 (en) 2020-09-17
SG11202008149RA (en) 2020-09-29
US20210380711A1 (en) 2021-12-09
IL276875A (en) 2020-10-29
RU2020130563A3 (https=) 2022-04-01
US20250034272A1 (en) 2025-01-30
WO2019169015A1 (en) 2019-09-06
BR112020017445A2 (pt) 2021-01-26
CN112424226B (zh) 2025-03-14
CA3091920A1 (en) 2019-09-06
MX2020008916A (es) 2021-02-15
KR20200128415A (ko) 2020-11-12
RU2020130563A (ru) 2022-03-28
CN112424226A (zh) 2021-02-26
ZA202005320B (en) 2022-02-23
EP3759140A1 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
JP7695298B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP7572041B2 (ja) 重症喘息を処置するための組成物および方法
JP6995844B2 (ja) アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
US20120269826A1 (en) Anti-cd3 antibody dosing in autoimmune disease
JP7357120B2 (ja) シェーグレン症候群の治療に使用するための抗ｃｄ４０抗体
CN104755495A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
JP7164530B2 (ja) Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
HK1255972A1 (zh) 与白介素-33(il-33)介导的疾病有关的生物标志物及其用途
WO2019023410A1 (en) ANTI-TIM-1 ANTIBODIES AND USES THEREOF
US20220298241A1 (en) Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
CN111971307A (zh) 用于预防移植物排斥的抗cd40抗体
CN113271964A (zh) 化脓性汗腺炎治疗中使用的抗cd40抗体
JP2023520676A (ja) Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法
TW201520226A (zh) 泛－ｅｌｒ＋ｃｘｃ趨化因子抗體
CN107206075A (zh) 用cd154抗体治疗自身免疫性疾病
TW202235435A (zh) 抗cd38抗體及其用途
RU2796586C2 (ru) Антитела к cd6 для лечения тяжелой астмы
CN116635422A (zh) 抗cd38抗体及其用途
HK40042290A (en) Anti cd6 antibodies for treating severe asthma
CN112672759A (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
TW202021983A (zh) 用於嗜伊紅性氣喘之抗il-33療法
WO2024044675A1 (en) Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
CN121443309A (zh) 多发性骨髓瘤的治疗
HK40112692A (zh) 用莫苏尼妥珠单抗治疗系统性红斑狼疮(sle)的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241003

R150 Certificate of patent or registration of utility model

Ref document number: 7572041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150